COMPANY PR0FILE 2021 Delivering New Treatments, Creating Future Smiles Delivering New Treatments, Creating Future Smiles Medicine keeps advancing, but many people around the world still suffer from diseases with no cure. A reliable new drug can bring courage for tomorrow to many patients and their families, and also to every healthcare professional who wants to provide the very best treatment. That’s what drives us to pioneer new methods, work across disciplines, and bring together all of our strengths. Our aim is to offer courage and strength to all who are waiting for new treatments. Our hope is that every day will continue to be vibrant and healthy for everyone for years to come. Creating a future filled with smiles for all. This is our goal at Taiho Pharmaceutical. Corporate We strive to improve human health Philosophy and contribute to a society enriched by smiles. Taiho Pharmaceutical is making diverse contributions to sustainability, always working for better health and more smiles for people around the world. Delivering New Treatments, Creating Future Smiles Medicine keeps advancing, but many people around the world still suffer from diseases with no cure. A reliable new drug can bring courage for tomorrow to many patients and their families, and also to every healthcare professional who wants to provide the very best treatment. That’s what drives us to pioneer new methods, work across disciplines, and bring together all of our strengths. Our aim is to offer courage and strength to all who are waiting for new treatments. Our hope is that every day will continue to be vibrant and healthy for everyone for years to come. Creating a future filled with smiles for all. This is our goal at Taiho Pharmaceutical. Corporate We strive to improve human health Philosophy and contribute to a society enriched by smiles. Taiho Pharmaceutical is making diverse contributions to sustainability, always working for better health and more smiles for people around the world. COMPANY PROFILE 2021 2 A Specialty Pharma with Strengths in Oncology Pharmaceutical Business Three Allergy/ Focus Oncology Immunology Urology Areas がん分 野に強みを持つ スペ シ ャリティファ ー マ （医療用医薬品事業） 3つの 免 疫・ Taiho 注力領域 がん アレルギー 泌尿器 Consumer Healthcare Pharmaceutical A Specialty Pharma with Business Supporting Strengths in Oncology People’s Health in Numbers Pharmaceutical Business ‍Taiho‍Pharmaceutical‍works‍hard‍every‍ day to support people’s health and Three Allergy/ bring more smiles to the world. The Focus Oncology Immunology Urology figures‍here‍illustrate‍the‍uniqueness‍of‍ Areas Taiho Pharmaceutical’s businesses and strengths as a company. 健 康 をサポートする コンシューマーヘルスケア Countries Where LONSURF Has Been Approved Oncology Products Consumer Healthcare Business Supporting People’s Health 93 Countries and Regions 72.1% of Sales ‍(2020) ‍(as‍of‍Dec.‍2020) ‍LONSURF,‍a‍drug‍discovered‍by‍Taiho‍Pharmaceutical,‍was‍launched‍in‍2014‍ Oncology products account for a large proportion of Taiho as‍a‍treatment‍for‍colorectal‍cancer.‍It‍has‍been‍approved‍in‍93‍countries‍ Pharmaceutical’s‍sales:‍72.1%‍of‍¥140.1‍billion.‍While‍taking‍on‍the‍ and‍regions‍around‍the‍world.‍In‍2019,‍an‍additional‍indication‍for‍gastric‍ challenge of creating anticancer drugs with diverse mechanism of action cancer was obtained in Japan, the U.S., and Europe, and this indication has leveraging‍its‍strengths‍in‍oncology,‍Taiho‍Pharmaceutical‍also‍works‍on‍ now‍been‍approved‍in‍over‍60‍countries‍and‍regions‍worldwide. developing‍novel‍drugs‍in‍the‍fields‍of‍allergy/immunology‍and‍urology. 3 COMPANY PROFILE 2021 Taiho Pharmaceutical in Numbers Taiho Percentage of Employees Taking R&D Expenses to Net Sales Childcare Leave 26.6% ‍(2020) Women100% Men 77.1% ‍(2020) ‍Taiho‍Pharmaceutical‍focuses‍on‍in-house‍drug‍discovery,‍allocating‍26.6%‍ The‍percentage‍of‍women‍taking‍childcare‍leave‍is‍100%.‍The‍percentage‍of‍ of its sales to R&D expenses for new drugs. In its ongoing pursuit of research men‍taking‍leave‍is‍increasing‍year‍by‍year.‍Taiho‍Pharmaceutical‍provides‍ and development of innovative new drugs that can support people’s health support‍for‍employees‍to‍balance‍work‍with‍raising‍children.‍This‍includes‍ worldwide,‍the‍company‍leverages‍its‍network,‍which‍goes‍beyond‍research‍ both systems and facilities, such as interviews during pregnancy, before institutions‍in‍Japan‍to‍include‍the‍U.S.,‍Europe,‍and‍other‍parts‍of‍Asia. maternity leave, and before returning from childcare leave, subsidies for babysitting‍expenses,‍and‍an‍on-site‍daycare‍center‍in‍the‍Tsukuba‍Area. Sales of Tiovita Drink Series Pioneering Oral Anticancer Drugs Since Approx.140,000,000 1974 bottles/year ‍(2020) In‍1974,‍when‍oral‍anticancer‍drugs‍were‍still‍uncommon,‍Taiho‍ Tiovita‍Drink‍is‍a‍nutritive‍energy‍drink‍which‍represents‍the‍company’s‍ Pharmaceutical launched Futraful, an oral tegafur formulation. Since then, Consumer‍Healthcare‍Business.‍A‍long-seller‍since‍1964,‍it‍sells‍ the company has launched a series of oral anticancer drugs developed approximately‍140‍million‍bottles‍per‍year,‍for‍a‍cumulative‍total‍of‍up‍to‍ in-house:‍UFT,‍TS-1,‍and‍LONSURF. 6.2‍billion‍bottles‍over‍the‍years. COMPANY PROFILE 2021 4 Looking toward global expansion, especially in ASEAN countries, Taiho Pharmaceutical will continue History of Taiho Pharmaceutical to research and develop new and Taiho‍Pharmaceutical‍has‍been‍in‍the‍business‍of‍pharmaceuticals‍(prescription‍drugs),‍including‍anticancer‍ unique products that meet people’s needs and enrich their lives. drugs,‍since‍its‍early‍days‍in‍the‍1960s.‍Beginning‍with‍Tiovita‍Drink,‍its‍business‍also‍includes‍consumer‍ healthcare‍products‍that‍can‍be‍purchased‍at‍pharmacies‍and‍drug‍stores.‍All‍along,‍Taiho‍Pharmaceutical‍ has focused on these two businesses, both closely connected to people’s health and smiles. 2020 2020 History of the Consumer Healthcare Business 2001 Harncare, a herbal medicine An anti- Taiho Pharmaceutical meets people’s needs and supports for mild incontinence bacterial/viral healthy,‍fulfilling‍lifestyles‍with‍products‍such‍as‍the‍Tiovita‍ and‍frequent‍ barrier that is series,‍the‍Solmack‍series,‍and‍Harncare.‍ urination, effective for 24 launched in hours Japan 2000 2000 2000 2000 2018 Efil, a virus removal/antibacterial 1979 spray, launched in Japan Solmack,‍an‍herbal‍digestive‍ Taiho‍Pharmaceutical‍created‍Efil,‍a‍product‍combining‍ethanol‍ support‍drink,‍launched‍ with silver and zinc ions. In addition to immediate removal of in Japan and TV viruses,‍bacteria,‍and‍odors,‍the‍antibacterial/antiviral‍effect‍ commercials keeps‍bacteria‍and‍viruses‍away‍for‍24‍hours.‍Efil‍can‍simply‍ started be‍applied‍to‍clothes‍and‍belongings‍before‍going‍out‍to‍keep‍ 1975 bacteria and viruses away while outside the home. TV commercials 1980 1980 1980 1980 1964 for‍Tiovita‍Drink‍ 2017 Pitas Sore Throat Troche started launched in Japan Tiovita 2010 Drink‍ Taiho Pharmaceutical launched the Pitas series launched Tiovita Drink bottle lightened to‍solve‍the‍throat-related‍worries‍of‍working‍ in Japan The structure of the bottle was improved people. Pitas Sore Throat Troche relieves throat to reduce the environmental impact of pain‍and‍swelling.‍It‍sticks‍to‍the‍roof‍of‍the‍ transportation and save resources. The mouth,‍so‍can‍be‍used‍even‍while‍speaking.‍It‍ Please refer to each product’s was designed for use in business meetings and brand site for their precautions company successfully developed a lighter when communicating with customers. for use. 1960 bottle while maintaining strength and capacity. 1960 5 COMPANY PROFILE 2021 History of Pharmaceutical Business (Anticancer Drug Development) Leveraging extensive evidence and a wealth of experience gained over half a century of anticancer drug Encountering Futraful: The Pursuing the Pioneering the Future of Cancer Treatment: development, Taiho Pharmaceutical Beginning of Our Anticancer Advancement of Continuing to Improve Patients’ Quality of Life will continue to develop new drugs Drug Development Anticancer Drugs: that contribute to cancer patients In‍2013,‍Taiho‍Pharmaceutical‍launched‍TS-1‍as‍the‍ Overcoming Various around the world. In‍1969,‍Taiho‍Pharmaceutical’s‍ world’s‍first‍anticancer‍agent‍in‍orally‍disintegrating‍(OD)‍ Challenges first‍president,‍Yukio‍Kobayashi,‍ tablet‍form.‍This‍helps‍to‍improve‍the‍quality‍of‍life‍of‍ 2020 visited the former Soviet Union In‍1984,‍Taiho‍Pharma- patients‍since‍it‍can‍be‍taken‍with‍or‍without‍water.‍ 2020 for‍business‍discussions.‍While‍ ceutical launched UFT, a In recent years, Taiho Pharmaceutical has been there, he encountered Futraful, a combination of uracil with conducting R&D aimed at comprehensive derivative* of a novel anticancer Futraful. Having moved care in oncology, including cancer drug,‍5-fluorouracil‍(5-FU)‍created‍ supportive care. 93 forward with research, in Countries in‍Latvia.‍Kobayashi‍sensed‍ 1999,‍the‍company‍launched‍ approving its great potential. He instantly TS-1,‍which‍combined‍ 2013 LONSURF 77 decided to conduct clinical trials gimeracil and oteracil TS-1‍combination‍OD‍ in Japan, and the company 65 potassium, with Futraful, the tablet launched in Japan succeeded in development after principal component. overcoming‍many‍hurdles.‍In‍1974,‍ 44 2000 the oral anticancer drug Futraful, 2000 2000 which enabled long-term oral 2000 34 administration, was developed together with an injectable. Futraful 2014 enabled outpatient therapy due to its 1 2 long-term oral administration, later LONSURF combination tablet leading to the establishment of the launched in Japan 2014 2015 2016 2017 2018